DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Google Secures Pentagon AI Deal for Classified Projects 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
 Technology - EconoTimes)
HAMILTON, Bermuda, April 12, 2017 -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative off-the-shelf cellular therapy for the treatment of solid tumor cancers announced today that the European Patent Office has granted European Patent No. 2496244. This patent covers claims related to methods of combining chemotherapy and immunotherapy for the treatment of cancer. This new patent supports our scaffold approach to building an intellectual property portfolio allowing the novel combination of multiple modes of therapy for the treatment of cancer.
The compositions covered by the patent generally relate to genetically modified natural killer (NK) cells that confer resistance to a chemotherapy agent. The claimed compositions can be used to protect immune cells from drug induced toxicities, thereby allowing for the combined administration of immuno- and chemotherapy. When dosed together, such combinations can result in anti-tumor responses by the chemotherapy, and reduces the immunosuppressive effects of the tumor while driving enhanced immune-mediated tumor cell killing, a treatment termed “drug resistant immunotherapy” or DRI.
“As novel combinations of chemotherapy and immunotherapies expand across the treatment landscape, the ability to protect immune cells from the toxic effects of chemotherapy in order to maintain a functional immune response is crucial to better long-term outcomes in patients undergoing cancer treatment,” said William Ho, Chief Executive Officer of Incysus.
This patent is owned by Incysus’ academic collaborators at Emory University, the Children’s Hospital of Atlanta (CHOA) and the University of Alabama at Birmingham (UAB), and is licensed exclusively to Incysus for all therapeutic purposes. Incysus and the UAB are moving quickly towards an investigational new drug application (IND) filing with the U.S. FDA to test the safety and efficacy of DRI γδ T cells in patients with glioblastoma.
About Incysus, Ltd.
Incysus is a Bermuda incorporated company focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified γδ T cells, our technology addresses the challenges that immunotherapies face targeting cold, low mutation, cancers. The Company's immuno-oncology programs with its collaborators include activated and gene modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells.
Contact: Incysus, Ltd (646) 820-8474 [email protected] www.incysus.com
